Peroxisome proliferators such as the fibrates act via the peroxisome proliferator activated receptor (PPAR)-α as hypolipidemic agents. Many peroxisome proliferators are also nongenotoxic hepatic carcinogens and hepatotoxicants in rodents. We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity. Additionally, the transcription profiling, histopathology, and clinical chemistry results suggested a biphasic response to clofibrate. These findings provide insight into the pathogenesis of toxic and carcinogenic effects of clofibrate in rodents and demonstrate the ability of cDNA microarrays to provide information regarding mechanisms of toxicity identified during the drug development process.
INTRODUCTION
The fibrate class of hypolipidemic agents such as clofibrate, benzafibrate, and fenofibrate are members of a large group of structurally diverse compounds known as peroxisome proliferators (PP). Peroxisome proliferators act as agonists for the peroxisome proliferator activated receptor (PPAR)-α, a member of the nuclear hormone receptor family (18) . PPARα regulates the expression of genes containing one or more peroxisome proliferator response elements (PPRE) in their promoter region, and is activated by endogenous fatty acids and eicosanoids (52) . A number of xenobiotic agents and environmental toxins, including certain pesticides, plasticizers and industrial chemicals act as agonists for PPARα. Among the receptor-mediated effects of PPs are hepatomegaly, increased fatty acid β-oxidation, and an increase in the number and volume of peroxisomes in responsive tissues (7, 26, 30) . Peroxisome proliferation is most pronounced in the liver, and is frequently associated in rodents with increased liver weight. The effects of PPs are highly species dependent, with rodents being highly sensitive, while humans and nonhuman primates are relatively nonrespondent (15) . This is likely due to lower receptor density in primates compared to rodents (53) .
Besides being potent hepatotoxicants, many PP, including clofibrate, are nongenotoxic rodent carcinogens (36) . Several laboratories have demonstrated that as a class, PPs are nongenotoxic (39) and do not act as tumor initiators (54, 56) , though they possess tumor promoting activity in initi-ated cells (23, 50, 55) . A central role for oxidative stress due to excess hydrogen peroxide (H 2 O 2 ) generation has been proposed as a mechanism for PP-mediated carcinogenesis in rodents (37, 38) . For example, the peroxisome proliferator and nongenotoxic rodent carcinogen, di-(2-ethylhexyl)phthalate (DEHP) has been shown to increase the expression of H 2 O 2 -producing acyl-CoA oxidase (11, 31, 32) . According to the oxidative stress hypothesis, production of H 2 O 2 would exceed the ability of the endogenous antioxidants to degrade it following treatment with high doses of PPs. Direct evidence for generation of hydroxyl radicals by PP in vivo (47) , and PP-mediated oxidative DNA damage (34) have been reported. Increased levels of 8-hydroxy-2 -deoxyguanosine, a biomarker of DNA damage caused by hydroxyl radicals, were also observed by some investigators in both the nuclei and mitochondria of rodent livers following treatment with ciprofibrate (21, 32) . In contrast, others have been unable to identify DNA damage or lipid peroxidation upon treatment with several PPs, including clofibrate (13, 16) , nor does increased acyl Co-A oxidase activity correlate with tumorigenic potency (27) , though it has been shown to be a good marker for PP-induced cell proliferation (7) .
An alternative theory implicates a role for cell proliferation in the mechanism of nongenotoxic carcinogens, including PP (12, 49 ). An induction of proliferation and a deregulation between hepatocellular proliferation and apoptosis both in vitro and in vivo has been reported by several investigators (6, 14, 27, 41) . The increased proliferation may be caused by PPmediated induction of nuclear factor kappa B (NF-κB) in Kupffer cells resulting in secretion of mitogenic stimuli (8, 43, 44) . Additionally, co-treatment with dexamethasone, an inhibitor of proinflammatory cytokine release, inhibited PPmediated cell proliferation but not peroxisome proliferation (25) . A third mechanistic hypothesis suggests that both mechanisms detailed above may work conjointly, since NF-κB is 417 418 KRAMER ET AL TOXICOLOGIC PATHOLOGY activated in response to reactive oxygen species (ROS) including H 2 O 2 (45, 46) . We performed transcription profiling on livers from rats treated for 5 days with one of 3 dose levels of clofibrate. The transcription profiling results were commensurate with an oxidative stress mechanism of hepatic injury. Additionally, the transcription profiling, histopathology, and clinical chemistry results demonstrated that the high-dose group was distinct from the lower dose groups. These results and those of other laboratories performing transcription profiling on peroxisome proliferator treated rodent livers (11) indicate that microarrays can help improve mechanistic understanding of target organ toxicity by identifying changes in the regulation of specific toxic response pathways.
METHODS
In vivo experiments. All experimental procedures were approved by the Pharmacia Institutional Animal Care and Use Committee and were performed in compliance with laws regarding humane treatment of laboratory animals. Clofibrate was suspended in 0.5% methylcellulose (w/v) plus 0.1% polysorbate 80 (v/v) in distilled water. Prior to treatment, male CD:IGS rats (Charles River Laboratories, Wilmington, MA), ages 6-7 weeks, were acclimated for 1 week then randomly assigned to dosage groups. All animals were housed individually in rooms set to maintain 72
• ± 5
• F (22 • ± 3
• C) and 40% humidity with a 12-hour light, 12-hour dark cycle. Groups of 3 animals were dosed once daily by oral gavage with 200, 400, or 800 mg/kg/day clofibrate or vehicle for 5 days. In rat bioassays Clofibrate at 200 mg/kg/day and 400 mg/kg/day induced liver tumors in Fisher rats (36) . Higher doses are well tolerated in shorter repeat dose studies, so the top dose in the present study was 800 mg/kg/day. Animals were fed ad libitum during the course of the study, and were not fasted prior to sacrifice. Animals were weighed at the outset of the study, and immediately prior to sacrifice. Prior to sacrifice blood was collected from the abdominal aorta of animals anesthetized with CO 2 -O 2 . Serum chemistry parameters analyzed included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), sorbitol dehydrogenase (SDH), cholesterol (Chol), total bile acids (BA), triglycerides (TG), glucose (Gluc), urea (BUN), creatinine (Creat), total bilirubin, total protein, albumin (Albu), sodium, potassium, chlorine, calcium, and inorganic phosphorus levels. Globulin (Glob) levels and the albumin to globulin ratio (A/G) were calculated from total protein and albumin levels. Livers were collected from each animal, weighed, then portions of each were frozen in liquid nitrogen for transcription profiling analysis. Livers were also sampled (1 slice of the right medial lobe and 1 slice of the left lateral lobe), fixed in 10% neutral buffered formalin for 24 hours, and subsequently routinely processed and embedded in paraffin. Histological sections of each liver were prepared and stained with hematoxylin and eosin.
Immunohistochemistry: Paraffin sections (5 µm) were dried at 37
• C for 1 hour and at 60
• C for 15-20 minutes. Deparaffinization and antigen retrieval were performed in 1X Reveal solution using a Decloaking chamber (Biocare Medical, Walnut Creek, CA). Endogenous peroxidase activity was blocked by a 10-15 minute incubation with PeroxiDazed 1 (Biocare Medical). Slides were then incubated with a polyclonal antibody (Cell signaling, Beverly, MA) that specifically recognized the large fragment of activated caspase-3 (1:100 dilution) for 1 hour at room temperature. After washes, slides were incubated with biotinylated goat anti-rabbit IgGs (Biocare Medical) for 30 minutes. Additionally, a mouse monoclonal antibody (PC10, Santa Cruz, CA) against proliferating cell nuclear antigen (PCNA) was biotinylated with the MM biotinylation kit (Biocare Medical) according to the manufacturer's instructions and applied at a 1:100 dilution to sections for 1 hour at room temperature. After 3 washes in PBS buffer, all sections were incubated with streptavidin horseradish-peroxidase (Vector, Burlingame, CA) followed with DAB chromogen (Dako, Carpinteria, CA), and counterstained with hematoxylin.
Computer-Assisted Image Analysis: For quantification of cell proliferation, 6 digital images were captured (at 200X magnification) with a charge-couple device (CCD) camera from each slide by selecting areas two fields in from the edge of the tissue spaced in thirds across the tissue. Digitized images were electronically recorded on a computer with a framegrabber board. The total number of cells per field and the number of PCNA labeled cells per field were counted using Optimas 6.5 software (Optimas Corp, Bothell, WA) using segmentation techniques to distinguish negative from positive nuclei. The segmentation process resulted in the generation of binary images from which the number of stained objects and the total number of nuclei was determined. Using these data, a ratio of positively labeled nuclei/total nuclei was calculated to determine the PCNA labeling index.
PCNA Labeling Index (LI) = PCNA labeled nuclei Total nuclei counted × 100
(1)
For evaluation and quantification of apoptosis, positively stained cells were counted manually for entire liver sections. Areas for each liver section were measured using Optimas 6.5 and a ratio of positive cells per area was calculated to determine the caspase-3 labeling index.
Caspase-3 Labeling Index (LI) = Caspase-3 labeled cells Total area units × 100 (2) Transcription Profiling: Total RNA was prepared from frozen livers using RNA-Stat reagent and protocol (Leedo Medical Laboratories, Houston, TX). Poly(A) + RNA was isolated using micro poly(A)plus kits (Ambion, Austin, TX). Aliquots of 200 ng of mRNA were used to generate Cy3 and Cy5 labeled cDNA probes using GEMBrite probe labeling kits (Incyte Pharmaceuticals, Palo Alto, CA). Individual treated and control sample probes were labeled with Cy5, while a pool of equal proportions of the 3 control group mRNAs was used to generate Cy3 labeled cDNA probes. Labeled probes were purified away from unincorporated primer using Chromaspin TE-30 columns (Clontech, Palo Alto, CA). Probe hybridization using RatGEM 1.0, containing ∼7,800 cloned rat cDNAs spotted on glass slides, was performed at Incyte Pharmaceuticals as previously described (48) . Probes from each of the three individual animals in all Vol. 31, No. 4, 2003 EXPRESSION PROFILING WITH CLOFIBRATE 419 three dose groups and the vehicle control group were prepared and hybridized against pooled control on two separate days. Each microarray was evaluated with respect to five parameters, background correction, log balance coefficient, absolute average signal, differential expression ratio, and differential percentage. Signal intensities in the Cy3 and Cy5 channels were normalized using total average signal intensity in both channels to generate a balance coefficient. A balanced differential expression (BDE) value was generated for every element that met minimum signal intensity and signal to background criteria. All those elements that contained Incyte unique proprietary sequences were excluded from the present analysis. Elements with signal intensities P1 + P2 < 500, signal to background values P1 STB + P2 STB < 10, or area of coverage less than 40%, were recorded as absent values and were omitted from further consideration. The BDE represents a fold change in expression relative to control, and BDE values were calculated using equation 3,
where P1 represents the Cy3 labeled pooled control sample signal intensity and bP2 represents the balanced Cy5 labeled treated sample signal intensity.
Microarray Element Nomenclature Reverification:
To confirm the identity of key elements on the array, the sequences of clones regulated 1.8-fold or greater was used to BLAST an internal Pharmacia copy of the GenBank nonredundant sequence database to ensure proper gene identification prior to analyzing the transcription profiling results (1) . Elements that matched a public rat sequence with a BLAST E value better than 1 × 10 −100 were named according to the best hit, and differences between the public and Incyte sequences were assumed to represent sequencing errors. Elements that matched a public sequence from another species with an E-value better than 1 × 10 −100 were assumed to be the rat orthologue of the public sequence. These sequences are not immediately obvious from the gene expression tables (Tables 2-7) , though the GenBank accession numbers provided will yield a sequence from a species other than rat. Sequences for which the best match in the public database yielded an E value between 1 × 10 −70 and 1 × 10 −100 were arbitrarily annotated as "homologue of" the gene that it best matched. Sequences that gave an E value between 1 × 10 −8 and 1 × 10 −70 were annotated as "similar to" the best match. In cases where more than 1 element represented the same gene, an average of all elements was calculated for each hybridization. Upon verifying the identity of each element, the genes were classified into one of a number of broad classes describing the general function of the gene product.
Hierarchical Clustering and Principal Components Analysis: Hierarchical clustering was performed using complete linkage and a correlation similarity method using Spotfire TM with all elements for which 22 or more of the 24 hybridizations passed element-level QC parameters. Principal component analysis was performed using Partek Pro version 5.0 (Partek Inc, St Charles, MO) with all elements for which 22 or more of the 24 hybridizations passed element-level QC parameters. The principal component analysis scatter plot was created using a correlation matrix, which scales each variable to a mean of zero and a standard deviation of 1. Prior to these analyses, expression values were converted to fractional balanced differential expression values (fBDE), indicative of a percent change in expression, using equation 4. fBDE = (bP2 − P1)/MIN(P1, bP2) (4) When calculating an fBDE, the signal intensity in the Cy3 channel (P1, pooled control sample) was subtracted from the balanced signal intensity in the Cy5 (bP2, treated sample) channel. This value was then divided by the smaller of the two signal intensities. Unlike the BDE value, fBDE is continuous from −∞ through +∞.
Verification of Selected Expression Profiling Results: Microarray based changes in the expression of several genes were verified using either quantitative polymerase chain reaction (Q-PCR), or Althea multiplex gene expression analysis. Q-PCR was performed using the ABI Prism 7700 sequence detector (Applera Corp., Foster City, CA) using primers and dual labeled probes designed to selectively amplify and de- 15 primer at 37
• C for 1 hour. Amplification was performed in 25 µL reaction volumes using 50 ng of cDNA. Amplifications were carried out using 1X PCR Buffer A, 2-3 mM MgCl 2 , 300-600 nM of gene-specific forward and reverse primers, 100-200 nM of gene-specific probe, 200 µM dNTP, and 1 U Amplitaq Gold (Applied Biosystems, Foster City, CA). Cycle conditions included a 10-minute 95
• C hot start followed by 40 cycles consisting of a 15s 95
• C melting step followed by a 1-minute 57
• C annealing and elongation step. The CT values were converted to relative expression levels in individual animals by adjusting for expression levels of the housekeeping gene cyclophilin. Althea multiplex gene expression analysis was performed in triplicate at Althea Technologies, Inc (San Diego, CA) as previously described (20) .
RESULTS

In Vivo and Postmortem Study
Results. All doses were well tolerated and no mortality was observed. No gross abnormalities were noted at necropsy except for a pronounced increase in liver weight in the clofibrate-treated Values in boldface were shown to be statistically significant ( p ≤ 0.05).
rats. Histological examination revealed slight to mild diffuse dose-dependent centrilobular hepatocellular hypertrophy at all 3 dose levels of clofibrate ( Figure 1 ). Although the glycogen content was high in the control and low-dose animals, it was markedly reduced in the centrilobular area of the middose animals and throughout the lobules in the high-dose animals. Additionally, the 800 mg/kg/day animals exhibited a multifocal increase in the number of centrilobular apoptotic bodies and increased multifocal centrilobular mitotic activity ( Figure 1 ). Selected physical parameters and clinical chemistry results are presented in Table 1 . The liver-to-body weight ratio was significantly increased at all dose levels. Serum ALT levels were significantly and dose-dependently increased, whereas AST levels were significantly increased only in the 800 mg/kg/day group. Serum cholesterol was significantly and dose-dependently decreased (Table 1) , but there was no change in total bile acid levels (data not shown). Triglycerides were also significantly decreased in all 3 treatment groups, though a clear dose response was not evident. Serum glucose levels were significantly reduced in both the 400 and 800 mg/kg/day animals and BUN was significantly increased in the 800 mg/kg/day group. Albumin levels were modestly increased in the low-and mid-dose groups, while globulin levels were decreased at the highest dose.
Immunohistochemistry: Representative images of PCNA immunohistochemistry (panels E & F), a marker of cell pro-FIGURE 1.-Histopathology of Clofibrate Treated Rat Livers. Histopathological and immunohistochemical analysis of the livers of rats treated with clofibrate after 800 mg/kg/day for 5 days. A and C) H&E stained liver sections from a vehicle-control rat. B and D) H&E stained liver sections from a rat treated with clofibrate at 800 mg/kg/day. Mild centrilobular hepatocellular hypertrophy and occasional apoptotic bodies (black arrow) around the central vein (V) were observed. The glycogen content of hepatocytes was also diffusely reduced in clofibrate-treated animals, as evidenced by the stronger eosinophilia of the cytoplasm. E) PCNA immunohistochemistry of a liver from a vehicle-control rat counterstained with Hematoxylin. PCNA-immunolabeled nuclei were rare. F) PCNA immunohistochemistry of a liver from a rat treated with clofibrate at 800 mg/kg/day counterstained with Hematoxylin. An increased number of PCNA-immunolabeled nuclei were observed compared to the liver of vehicle-treated rats, indicating increased hepatocellular proliferation. G) Caspase-3 immunohistochemistry of a liver from a vehicle-control rat counterstained with Hematoxylin. Caspase-3-immunolabeled cells were rarely present in the liver of vehicle-treated rats. H) Caspase-3 immunohistochemistry of a liver from a rat treated with clofibrate at 800 mg/kg/day counterstained with Hematoxylin. A slightly increased number of caspase-3 immunolabeled hepatocytes were observed around central veins (black arrows) compared to vehicle-treated animals, suggesting a slight increase in apoptosis. This apparent increase in apoptosis was not present in the lower-dose groups and was not statistically significant in the 800 mg/kg/day dose group. Transcription Profiling: All microarray hybridizations passed minimal quality control parameters. Full microarray data has been submitted to the MIAME-Express database, accession number E-MEXP-3. Individual elements for which fewer than 6 of the 24 microarrays yielded signal that met the element-level QC criteria described were omitted from consideration. This resulted in 5,946 of the 7,872 elements that were used for further analyses. Of the 5,947 elements that passed all levels of QC, 314 elements representing 163 genes showed an average 2-fold or greater differential regulation in 1 or more dose group. Hierarchical clustering performed using Spotfire demonstrated that with the exception of the control animals, which had few gene expression changes relative to pooled control, individual rat arrays clustered most closely with their own technical duplicates, despite having been run several weeks apart, demonstrating reproducibility of the transcription profiles generated 422 KRAMER ET AL TOXICOLOGIC PATHOLOGY FIGURE 2.-Immunohistochemistry in the liver of clofibrate treated rats. A) Proliferation in the liver of clofibrate treated rats was assessed by immunohistochemistry using anti-PCNA antibodies and quantified by computer-assisted image analysis. Treatment with clofibrate caused significant increases in proliferation at all doses utilized. Additionally, the highest dose was significantly different from the low-and mid-dose groups. *Significantly (P ≤ 0.05) different from control, **significantly (P ≤ 0.05) different from control, low-, and mid-dose groups. B) Apoptosis was assessed by immunohistochemistry using an anti-activated caspase-3 antibody and quantified by computer-assisted image analysis. Although no significant changes were seen among study groups, the balance between proliferation and apoptosis was affected. CARAT enzyme function is necessary for progression through G1 and into the S-phase of the cell cycle. Average Balanced Differential Expression (BDE) for 200 (Lo), 400 (Md), and 800 (Hi) mpk clofibrate treated rats. GenBank accession number is indicated for each sequence (Acc #). All elements had BLAST E-Values of 0.0 when compared to the indicated GenBank sequence except as noted in the description column.
( Figure 3 ). Principal component analysis performed using Partek Pro 5.0 demonstrated a separation of the high dose group, while the low and mid dose animals were intermingled ( Figure 4) . In both analyses all treated animals clearly separated from control. All genes regulated an average of 2-fold or more in at least one dose group were categorized by general biological function and are shown in Tables 2-7 . Although changes below 2-fold may be biologically significant, the reliability of transcription profiling results below 2-fold may be questionable. Table 2 shows lipid-related genes whose expression was regulated in rat liver by clofibrate. The genes were divided into three sub-classes, specifically fatty acid beta oxidation, fatty acid, phospholipid and triglyceride synthesis, and lipid mobilization. Genes involved in fatty acid beta oxidation both in the peroxisome and the mitochondria were clearly induced. Induction of fatty acyl-CoA oxidase (FACO) was verified both by Q-PCR and Althea multiplexed expression profiling analysis (Table 8a ). The expression of a number of apolipoproteins, which are secreted by the liver and carry cholesterol and triglycerides to and from peripheral tissues, was repressed. Repression of apolipoprotein C-III (Table 8b) and A-IV (data not shown) was verified by Althea technology. Clofibrate also affected the expression of a number of drug and xenobiotic metabolism genes (Table 3) . Among these, induction of cytochrome P450 4A1 and cytochrome P450 reductase and repression of CYP1A2 were verified by Q-PCR (Table 8c ). Repression of hydroxysteroid sulfotransferase was verified by Althea multiplexed gene expression analysis technology (Table 8b) .
Many genes involved in proliferation and transcriptional control were regulated, whereas a smaller number of genes encoding apoptosis-related proteins were affected ( Table 4) . Repression of TSC-22 was verified both by Q-PCR and Althea multiplexed expression profiling analysis (Table 8a) . Induction of hepatic angiopoietin-related protein and repression of poly (ADP-ribose) polymerase 2 were confirmed by Q-PCR (Table 8c ). The expression of many genes encoding enzymes involved in normal cellular metabolic processes such as amino acid and carbohydrate metabolism were also altered ( Table 5 ). Most of this broad class of genes was modestly repressed, though many genes encoding enzymes involved in energy metabolism were induced. Induction of pyruvate dehydrogenase kinase-4 and nondose-dependent Average Balanced Differential Expression (BDE) for 200 (Lo), 400 (Md), and 800 (Hi) mpk clofibrate treated rats. GenBank accession number is indicated for each sequence (Acc #). All elements had BLAST E-Values of 0.0 when compared to the indicated GenBank sequence except as noted in the description column.
repression of phosphoenolpyruvate carboxykinase was confirmed by Althea technology (Table 8b) . A large number of genes encoding proteins involved in immunity, inflammation and coagulation were repressed, and several stress response genes were also affected by clofibrate ( Table 6) .
As well as inducing increased peroxisomal fatty acid beta oxidation, fibrates cause peroxisome proliferation. A number of genes encoding peroxisome structural proteins were regulated by clofibrate treatment (Table 7) , as were selected genes encoding proteins involved in membrane trafficking and transport. Induction of the type IIb sodium-phosphate transporter was confirmed both by Q-PCR and Althea multiplexed expression profiling analysis (Table 8a ). Finally, several genes encoding theoretical and unknown proteins and known proteins of uncertain function and genes encoding proteins that did not fit conveniently into the above groups were also included in Table 7 . DISCUSSION Peroxisome proliferators, including the fibrate class of hypolipidemic drugs, are a group of structurally diverse compounds that act as agonists for the peroxisome proliferator activated receptor (PPAR)-α. Among the receptor mediated hepatotoxic effects of PP are hepatomegaly due to cellular hypertrophy and hyperplasia (27) , likely due to oxidative stress. Clofibrate-mediated hepatic cellular toxicity in vitro has been shown to be prevented by antioxidants (35) . In general, rats are considerably more responsive than other toxicology species or humans to the hepatotoxic effects of PP. A large body of epidemiological and mechanistic evidence suggests that PPs present minimal risk to humans (4, 10 ). This conclusion is based largely on results demonstrating differences between rodent and primate PPAR-α expression levels and function (24, 53) . Many PPs are also nongenotoxic rodent hepatocarcinogens. Hypotheses for the mechanism of PP-induced hepatocarcinogenesis in rodents include the oxidative stress model, and the cell proliferation model. The oxidative stress hypothesis implicates reactive oxygen species (ROS) produced by peroxisome proliferation in initiation and promotion of carcinogenesis (37, 38) . The alternative hypothesis implicates deregulation between proliferation and apoptosis (19) . Average Balanced Differential Expression (BDE) for 200 (Lo), 400 (Md), and 800 (Hi) mpk clofibrate treated rats. GenBank accession number is indicated for each sequence (Acc #). All elements had BLAST E-Values of 0.0 when compared to the indicated GenBank sequence.
The oxidative stress hypothesis relies upon the fact that PPs induce fatty acid beta oxidation in the peroxisome (51). Steady-state fatty acid beta oxidation occurs in the mitochondrion where the first and rate-limiting enzyme is acyl-CoA dehydrogenase (28) . Peroxisome proliferator-induced beta oxidation favors the peroxisome, where the first and rate-limiting enzyme is fatty acyl-CoA oxidase (FACO). Unlike acyl-CoA dehydrogenase, FACO produces a single molecule of H 2 O 2 for each catalytic cycle (17) . It has been postulated that at high PP doses, the increased FACO activity results in H 2 O 2 levels that exceed the ability of the organism to degrade it. As the endogenous antioxidant machinery is overwhelmed, excess free ROS may lead to lipid peroxidation and DNA damage. Cellular degradation of H 2 O 2 and its by-products is typically performed within the cell by enzymes such as catalase, glutathione peroxidase and superoxide dismutase. Although direct measurements of indicators of oxidative stress were not performed in the present study, the expression of FACO was induced nearly 5-fold at the highest dose of clofibrate (Table 2) . Additionally, a number of base excision repair (BER) enzymes are regulated by ROS and have been shown to be induced by peroxisome proliferators (46) , and our results demonstrated that the BER gene DNA repair endonuclease XPF was induced by clofibrate (Table 6) . Signal intensities at the single catalase element present on RatGEM 1.0 were at or below background levels, indicating that PPinduced changes, if present, would not have been detected. Althea multiplex gene expression analysis demonstrated an absence of catalase regulation (Table 8b ). However, catalase is typically only regulated by ∼1.5-to 2-fold, which may be below the ability of these methods to demonstrate. Several glutathione peroxidase and superoxide dismutase elements were also present on the microarray, but their expression levels were not altered.
An alternative to the oxidative stress hypothesis proposed for PP-mediated rodent hepatocarcinogenesis implicates increased proliferation in the absence of increased apoptosis (42) . In the present study a statistically significant increase in cell proliferation, as assessed by PCNA immunohistochemistry, was not accompanied by a significant effect on apoptosis, as assessed by caspase-3 immunohistochemistry (Figure 2 ). Consistent with this finding, there were a number of genes related to proliferation and transcription affected by treatment with clofibrate, while relatively few apoptosisrelated genes were regulated in the current study (Table 4) . Cyclin D3 protein levels have been reported to be affected by the PP WY14,643 (40) , and cyclin D3 was among those genes whose expression was induced in the present study. It has been suggested that PPs cause liver enlargement and hepatocellular proliferation in rodents through ROS-mediated induction of the transcription factor NF-κB (45) , predominately in Kupffer cells (8, 44) . Conversely, others have suggested that PP-induced liver cell proliferation is not associated with NF-κB activation (29) . Although several NF-κB and IκB elements were present on RatGEM 1, no regulation of mRNA levels was observed in the present study. This may reflect Vol. 31, No. 4, 2003 EXPRESSION PROFILING WITH CLOFIBRATE 427 Average Balanced Differential Expression (BDE) for 200 (Lo), 400 (Md), and 800 (Hi) mpk clofibrate treated rats. GenBank accession number is indicated for each sequence (Acc #). All elements had BLAST E-Values of 0.0 when compared to the indicated GenBank sequence except as noted in the description column.
the transient nature of the induction of the genes encoding NF-κB subunits, which have been shown to return to baseline levels within 36 hours of treatment with PP in vivo (46) , and the use of a single time point after repeated doses in the present study. Additionally, Kupffer cells represent a small proportion of the liver and mitogenic transcriptional signals may be diluted in an analysis of the entire liver. Finally, it is possible that some of these gene products may be regulated posttranscriptionally, and thus would not be identified using transcription profiling.
Along with PP-mediated hepatocellular proliferation, suppression of apoptosis by PP both in vitro and in vivo has been reported (6, 14, 41) . However these studies have either used different PP (6, 41) , or significantly different dosing regimens (14) . Although no statistically significant effects on apoptosis as assessed by caspase-3 immunohistochemistry were seen in the present study, an analysis of the liver pathology data identified an increase in the number of apoptotic bodies primarily in the centrilobular area in the 800 mg/kg/day dose group (Figure 1) . Furthermore, the balance between proliferation and apoptosis was clearly disrupted, even in the relatively short timeframe of the current study. Finally, though not statistically significant, caspase-3 LI was trending down relative to control in the 200 and 400 mg/kg/day dose groups (Figure 2) . Among the apoptotic genes regulated was a sequence similar to mouse poly (ADP-ribose) polymerase 2 (PARP-2), which was repressed, and hepatic angiopoietin-related protein (HARP), which was induced. Poly (ADP-ribose) polymerases aid in DNA-base excision repair, DNA-damage signaling, and the regulation of genomic stability, and are involved in the execution phase of apoptosis (2) . PARP over activity may cause cell death. HARP is a fibrinogen/angiopoietin-related protein that reportedly prevents endothelial-cell apoptosis (22) .
In addition to effects on lipid and xenobiotic metabolism and proliferation, fibrates also affect other metabolic pathways, as summarized in Figure 5 . The expression of a number of cellular and energy metabolism enzymes was regulated by treatment with clofibrate in the present study (Table 5) . Among these, genes encoding amino acid, carbohydrate, and Average Balanced Differential Expression (BDE) for 200 (Lo), 400 (Md), and 800 (Hi) mpk clofibrate treated rats. GenBank accession number is indicated for each sequence (Acc #). All elements had BLAST E-Values of 0.0 when compared to the indicated GenBank sequence except as noted in the description column. nucleotide metabolism were mostly repressed, likely due to an increased demand for these chemical building blocks in the proliferating cells (several nucleotide metabolism genes were just below the 2-fold cutoff used, and do not appear in Table 5 ). In contrast HMG-CoA synthase, which catalyzes the formation of 3-hydroxy-3-methylglutaryl-CoA, a precursor of mevalonate for cholesterol biosynthesis (5), was increased ∼3-fold. It has been speculated that elevated cholesterol biosynthesis may serve as an early event in cell proliferation (33) . Pyruvate dehydrogenase kinase isoenzyme 4, (9) . The induction of this gene may reflect a reduced need for cellular metabolism of the products of glycolysis due to increased fatty acid beta oxidation ( Figure 5 ). Induced genes are shown in red text, repressed genes in blue and unaffected genes (BDE between 2 and −2) in gray. Key genes that were absent from the microarray are in black text on a gray background. Structures, pathways and chemical entities appear in black text. Within the peroxisome, the H 2 O 2 -producing fatty acyl-CoA oxidase (FACO) was increased, whereas catalase (CAT) was not significantly induced. Among the other mechanistic pathways with members affected by clofibrate were drug, hormone and xenobiotic metabolism; lipid mobilization; proliferation and transcriptional regulation; immunity, inflammation and coagulation; and amino acid, carbohydrate and nucleotide metabolism (several nucleotide metabolism genes, including 5 nucleotidase (NTase), were repressed but fell just below the 2-fold cutoff ). Acetyl-CoA carboxylase (ACC), also fell just below the 2-fold cutoff. Gene abbreviations appear within Tables 2-7. Additional abbreviations are as follows: Coenzyme A (CoA), fatty acid synthase (FAS), fatty acyl-CoA (FA-CoA), free fatty acids (FFA), high density lipoprotein (HDL), low density lipoprotein (LDL), low density lipoprotein receptor (LDL-R), nuclear factor kappa B (NF-κB), nuclear factor kappa B response element (NFRE), peroxisome proliferator activated receptor alpha (PPAR-α)s peroxisome proliferator response element (PPRE), retinoid X receptor (RXR), triglycerides (TG), and tumor necrosis factor (TNF)-α.
At the 800 mg/kg/day dose treatment with clofibrate resulted in the repression of numerous genes encoding proteins related to immunity, inflammation, and coagulation, and induction of several general stress response genes, indicative of a general stress response (Table 6 ). Others have reported deregulation of acute phase proteins upon treatment
